AGY THERAPEUTICS TO PRESENT AT INTERNATIONAL STROKE CONFERENCE
SOUTH SAN FRANCISCO, Calif. Feb. 2, 2005 - AGY Therapeutics Inc., a privately held biotechnology company, today announced that Roman Urfer, Ph.D., the Company’s senior vice president of drug discovery and development, will present at the International Stroke Conference this week. His presentation will focus on the discovery of a novel therapeutic for functional recovery after stroke, which the Company plans to move into Phase 2 clinical trials shortly. Dr. Urfer’s presentation will take place on Thursday, February 3 at
in room 391-392 at the
Current approaches to stroke treatment focus on saving neural cells within a narrow time window of hours after the insult to have any benefit. Because AGY’s product candidate is delivered orally days after a stroke and works by stimulating neuronal plasticity in surviving brain tissue, it represents an entirely new approach for treatment of stroke patients. There currently are no pharmaceutical agents available to enhance long-term functional recovery for stroke patients.
About AGY Therapeutics
AGY Therapeutics Inc., a privately held biopharmaceutical company, is dedicated to discovering and developing breakthrough central nervous system (CNS) therapeutics, including treatments for neurodegenerative diseases, CNS injuries, stroke, cognitive diseases and schizophrenia. With its proprietary imAGYneTM platform, the company has identified and characterized drug targets and compounds to treat these diseases. With a robust pipeline of clinical and preclinical candidates, the Company soon will start a Phase 2a trial of its lead product candidate for functional recovery from stroke.